• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by SenesTech Inc.

    11/12/24 4:30:48 PM ET
    $SNES
    Agricultural Chemicals
    Industrials
    Get the next $SNES alert in real time by email
    SC 13G 1 p24-3327sc13g.htm

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No.   )*
     

    SenesTech, Inc.

    (Name of Issuer)
     

     

    Common stock, par value $0.001 per share

    (Title of Class of Securities)
     

    81720R604

    (CUSIP Number)
     

    November 27, 2023 and December 31, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 81720R60413GPage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    PFS Cap Mgt Co

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Nevada

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    95,000 shares of Common Stock (including 30,000 shares of Common Stock issuable upon the exercise of warrants) (see Item 4)*

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    95,000 shares of Common Stock (including 30,000 shares of Common Stock issuable upon the exercise of warrants) (see Item 4)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    95,000 shares of Common Stock (including 30,000 shares of Common Stock issuable upon the exercise of warrants) (see Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99% (see Item 4)*

    12

    TYPE OF REPORTING PERSON

    CO

             

     

    * The information set forth above reflects the information as the date hereof. As of the date of event requiring the filing of this statement (the “Event Date”), the Reporting Persons may have been deemed to beneficially own 26,442 shares of Common Stock (including 15,000 shares of Common Stock issuable upon the exercise of warrants held by the Trust (as defined in Item 2(a)) (the “Reported Warrants”)) and representing approximately 9.99% of the outstanding shares of Common Stock as of such time. As of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 27,400 shares of Common Stock (including 15,000 shares of Common Stock issuable upon the exercise of the Reported Warrants) and representing approximately 9.99% of the outstanding shares of Common Stock as of such time.

     

    The positions reported as of the date of event requiring the filing of this statement and as of December 31, 2023 have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 24, 2024. As more fully described in Item 4, the Reported Warrants are subject to the 9.99% Blocker (as defined in Item 4) and the percentages set forth above give effect to the 9.99% Blocker. However, each position reported above is the number of shares of Common Stock that would be issuable upon the full exercise of the Reported Warrants at such time and do not give effect to the 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person at such time, after giving effect to the 9.99% Blocker, is less than the positions reported above.

     

    CUSIP No. 81720R60413GPage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    PFS Trust

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Nevada

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    95,000 shares of Common Stock (including 30,000 shares of Common Stock issuable upon the exercise of warrants) (see Item 4)*

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    95,000 shares of Common Stock (including 30,000 shares of Common Stock issuable upon the exercise of warrants) (see Item 4)*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    95,000 shares of Common Stock (including 30,000 shares of Common Stock issuable upon the exercise of warrants) (see Item 4)*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99% (see Item 4)*

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    * The information set forth above reflects the information as the date hereof. As of the Event Date, the Reporting Persons may have been deemed to beneficially own 26,442 shares of Common Stock (including 15,000 shares of Common Stock issuable upon the exercise of the Reported Warrants) and representing approximately 9.99% of the outstanding shares of Common Stock as of such time. As of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 27,400 shares of Common Stock (including 15,000 shares of Common Stock issuable upon the exercise of the Reported Warrants) and representing approximately 9.99% of the outstanding shares of Common Stock as of such time.

     

    The positions reported as of the date of event requiring the filing of this statement and as of December 31, 2023 have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 24, 2024.  As more fully described in Item 4, the Reported Warrants are subject to the 9.99% Blocker and the percentages set forth above give effect to the 9.99% Blocker. However, each position reported above is the number of shares of Common Stock that would be issuable upon the full exercise of the Reported Warrants at such time and do not give effect to the 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person at such time, after giving effect to the 9.99% Blocker, is less than the positions reported above.

     

    CUSIP No. 81720R60413GPage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER
      SenesTech, Inc. (the “Issuer”)

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      23460 N 19th Ave, Suite 110, Phoenix, AZ 85027

     

    Item 2(a). NAME OF PERSON FILING
     

    This report on Schedule 13G is being filed by: (i) PFS Cap Mgt Co, a Nevada corporation (“Mgt Co”) and (ii) PFS Trust, a Nevada trust (the “Trust”). Mgt Co indirectly controls the Trust, with respect to the Common Stock (as defined in Item 2(d) below) and the Common Stock underlying warrants directly held by the Trust.

     

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address for each of the Reporting Persons is 2207, Suite B, Bellanca St., Minden, Nevada 89423.

     

    Item 2(c). CITIZENSHIP
      Mgt Co is a Nevada corporation.  The Trust is a Nevada trust.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common stock, par value $0.001 per share (the “Common Stock”)

     

    Item 2(e). CUSIP NUMBER
      81720R604

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

     

     

    CUSIP No. 81720R60413GPage 5 of 7 Pages

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ___________________________________________

     

    Item 4. OWNERSHIP
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page hereto and is incorporated herein by reference for the Reporting Person.

    The percentages set forth as of the date hereof are calculated based upon 515,340 shares of Common Stock outstanding as of August 6, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2024, and assumes the exercise of the Reported Warrants held by the Trust, subject to the 9.99% Blocker (as defined below).

     

    The percentages set forth as of the Event Date and December 31, 2023 are calculated based upon approximately 94,260 shares of Common Stock outstanding, which is based on assuming the completion of the Common Stock offering described in the Issuer’s Prospectus filed pursuant to Rule 424(b)(4) with the SEC on November 29, 2023, as confirmed in the Issuer’s Current Report on Form 8-K filed with the SEC on November 29, 2023, and gives effect to the 1-for-10 reverse stock split effected by the Issuer on July 24, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the SEC on July 23, 2024, and assumes the exercise of the Reported Warrants held by the Trust, subject to the 9.99% Blocker.

     

    Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise any of the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the “9.99% Blocker”) and the percentage set forth on the cover page for each Reporting Person gives effect to the 9.99% Blocker. Consequently, at this time, the Reporting Persons are not able to exercise all of such Reported Warrants due to the 9.99% Blocker. In addition, as of the date of event requiring the filing of this statement and as of December 31, 2023, the Reporting Persons were not able to exercise all of such Reported Warrants due to the 9.99% Blocker.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    CUSIP No. 81720R60413GPage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below, each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 81720R60413GPage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 12, 2024

     

      PFS CAP MGT CO
       
       
      /s/ John David Kessler  
      Name: John David Kessler  
      Title: Director

     

      PFS TRUST
       
       
      /s/ John David Kessler  
      Name: John David Kessler  
      Title: Authorized Signatory

     

     

     

    Get the next $SNES alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SenesTech to Participate in the Lytham Partners 2025 Consumer & Technology Investor Summit on August 19, 2025

    SURPRISE, Ariz., Aug. 18, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in fertility control for managing animal pest populations, today announced that it will participate in a webcast presentation at the Lytham Partners 2025 Consumer & Technology Investor Summit, taking place virtually on Tuesday, August 19, 2025. The webcast will take place at 3:30 p.m. ET on Tuesday, August 19, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/cts2025/ or directly at https://lythampartners.com/cts2025/snes. A replay will also

    8/18/25 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins

    94% Revenue Growth in Evolve™ Rodent Birth Control Products Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., Aug. 7, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the second quarter ended June 30, 2025. Q2 2025 Highlights Revenues increased 36% to $625,000, a record for the Company, from $459,000 in Q2 2024.Evolve Rodent Birth Control products sales grew 94%

    8/7/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces Closing of Warrant Exercise for $6.3 Million in Gross Proceeds

    SURPRISE, Ariz., Aug. 5, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", )), a leader in fertility control for managing animal pest populations, announced today the closing of its previously announced exercise of certain outstanding warrants to purchase an aggregate of 1,458,872 shares of the Company's common stock originally issued by the Company on July 1, 2025, at the existing exercise price of $4.15 per share. H.C. Wainwright acted as the exclusive placement agent for the transaction. As consideration for the exercise of such existing

    8/5/25 7:10:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Graham Lynn Yako claimed no ownership of stock in the company (SEC Form 3)

    3 - SenesTech, Inc. (0001680378) (Issuer)

    8/14/25 5:09:06 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form 4 filed by Director Moss Joshua Matthew

    4 - SenesTech, Inc. (0001680378) (Issuer)

    1/10/25 4:44:49 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    New insider Moss Joshua Matthew claimed no ownership of stock in the company (SEC Form 3)

    3 - SenesTech, Inc. (0001680378) (Issuer)

    1/10/25 4:41:13 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Names Nicole Williams as Chief Revenue Officer

    PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye

    2/16/23 9:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces Appointment of Vector and Pest Control Industry Veteran Joel Fruendt as Chief Executive Officer

    PHOENIX, Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period. This leadership transition is part of SenesTech's ongoing strategic plan to drive the commercialization of ContraPest, its flagship product.

    11/14/22 9:10:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by SenesTech Inc.

    SC 13G - SenesTech, Inc. (0001680378) (Subject)

    11/12/24 4:30:48 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Financials

    Live finance-specific insights

    View All

    SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins

    94% Revenue Growth in Evolve™ Rodent Birth Control Products Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., Aug. 7, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the second quarter ended June 30, 2025. Q2 2025 Highlights Revenues increased 36% to $625,000, a record for the Company, from $459,000 in Q2 2024.Evolve Rodent Birth Control products sales grew 94%

    8/7/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern time PHOENIX, July 31, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in fertility control for managing animal pest populations, will report second quarter 2025 financial results for the period ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company has scheduled a conference call that same day, Thursday, August 7, 2025, at 5:00 p.m. Eastern time, to review the results. Second Quarter 2025 Conference Call Details Date and Time: Th

    7/31/25 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Reports First Quarter 2025 Financial Results 40% Revenue Growth in Evolve™, Record Gross Profit Margins of 65%, and Continued Progress Toward Profitability

    SURPRISE, Ariz., May 8, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the first quarter ended March 31, 2024. Q1 2025 Highlights Revenues increased 17% to $485,000 from $415,000 in Q1 2024.Evolve product sales grew 40% year-over-year, now representing 79% of total revenue.Gross profit margin expanded to 64.5%, a record for the Company, compared to 32.5% in Q1 2024.Net loss for Q1 2025 was

    5/8/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    SEC Filings

    View All

    SEC Form EFFECT filed by SenesTech Inc.

    EFFECT - SenesTech, Inc. (0001680378) (Filer)

    8/25/25 12:15:30 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form 424B3 filed by SenesTech Inc.

    424B3 - SenesTech, Inc. (0001680378) (Filer)

    8/22/25 4:16:35 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form S-3 filed by SenesTech Inc.

    S-3 - SenesTech, Inc. (0001680378) (Filer)

    8/15/25 4:24:01 PM ET
    $SNES
    Agricultural Chemicals
    Industrials